Track Globus Medical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Globus Medical, Inc. GMED · Stock Open Globus Medical, Inc. in new tab

72.14 USD
P/E
18.81
EPS
4.00
P/B
2.08
ROE
12.13
Beta
0.95
Target Price
93.43 USD
Globus Medical, Inc. logo

Globus Medical, Inc.

🧾 Earnings Recap – Q3 2026

Globus Medical fell 12.8% after earnings, as investors likely focused on near-flat total revenue, only 2% U.S. Spine growth, and delayed product launches and production issues that management said are limiting growth until 2027. Nevro’s 25.7% decline added to the drag, despite growth in enabling technologies and higher EPS.

  • Q3 revenue was $763.7 million, down 0.7% reported and 0.5% in constant currency. Base business excluding Nevro grew 3% to $690 million; Nevro revenue fell 25.7% to $73.7 million.
  • U.S. Spine grew 2%. Management attributed the slowdown to delayed product launches, lingering production issues and lower contributions from competitive recruiting; it expects launches to support growth entering 2027.
  • Enabling Technologies revenue rose 24% to $34.9 million. EGPS and eHub units deployed, including sold, leased or rented units, increased 73% year over year.
  • Non-GAAP EPS was $1.23, up 4% year over year, and free cash flow reached a record $225 million despite a 13% increase in capital expenditures.
  • The company repurchased 1.9 million shares for $143 million. SCRIPT implants and rods are available; the XLIF Prone Solution and 2-Blade Retractor are expected later this quarter, while EIQ is in final introduction stages and is expected to contribute meaningfully in 2027 and beyond.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
P/E18.81
EPS4.00
Book Value36.15
Price to Book2.08
Debt/Equity2.26
% Insiders0.743%
Growth
Revenue Growth-0.01%
Earnings Growth0.18%
Estimates
Forward P/E14.10
Forward EPS5.34
Target Mean Price93.43

DCF valuation

Model fair value for Globus Medical, Inc. (GMED)
Result
Sign in to run the valuation for GMED.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Buy · mean target 93.43 USD (low 75.00, high 110.00) · as of 11 Nov 2026
Low 75.00
Mean 93.43
High 110.00
Price 72.14
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Globus Medical, Inc. Logo Globus Medical, Inc. Analysis (GMED)

United States Health Care Official Website Stock

Is Globus Medical, Inc. a good investment? Globus Medical, Inc. (GMED) is currently trading at 72.14 USD. Market analysts have a consensus price target of 93.43 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 18.81. This valuation is generally in line with the broader market.

Earnings Schedule: Globus Medical, Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is 5.34.

Investor FAQ

Does Globus Medical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Globus Medical, Inc.?

Globus Medical, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of 4.00.

Company Profile

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Exchange Ticker
NYQ (United States) GMED
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion